MDXG
NASDAQ · Biotechnology
Mimedx Group Inc
$4.77
+0.08 (+1.71%)
Open$4.65
Previous Close$4.69
Day High$4.80
Day Low$4.61
52W High$7.97
52W Low$3.03
Volume—
Avg Volume1.03M
Market Cap689.45M
P/E Ratio110.51
EPS$0.04
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+406.3% upside
Current
$4.77
$4.77
Target
$24.15
$24.15
$19.42
$24.15 avg
$35.38
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 411.02M | 354.15M | 190.63M |
| Net Income | 47.69M | 36.98M | 27.70M |
| Profit Margin | 11.6% | 11.0% | 14.5% |
| EBITDA | 64.11M | 52.48M | 34.17M |
| Free Cash Flow | — | — | 29.04M |
| Rev Growth | +16.1% | +16.1% | +8.9% |
| Debt/Equity | 0.07 | 0.07 | 0.66 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $264.48 | +0.20% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $393.16 | +1.95% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $150.56 | +0.30% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $510.72 | +0.47% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $798.17 | +1.70% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $244.32 | +1.99% | 40.0 | 32.33B |